BiVictriX Interim results for the six months ended 30 June 2021

Blog image
  • Collaborations progressed with leading academic centres
  • Further strengthening of intellectual property portfolio
  • Successful Initial Public Offering ("IPO”)on AIM raising £7.5 million (gross) of new funding
  • Highly experienced Board appointed

Alderley Park, 22 September 2021 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces its maiden unaudited results for the six months ended 30 June 2021.

Please Read PDF RNS Here

newsletter

Contact BivictriX

Please submit the form below and we shall be in touch
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
AntibodyPatient Image